QUEBEC CITY, Dec. 22, 2014 /CNW Telbec/ - Opsens Inc. ("Opsens") (TSXV: OPS) is pleased to announce the first use of its Fractional Flow Reserve ("FFR") products in several patients during the 21st Kamakura Live Demonstration Course 2014 (www.kamakuralive.net) in Yokohama (Japan) by Dr. Shigeru Saito. The OptoWire and OptoMonitor are Opsens' products for FFR measurements to optimize the diagnosis and guide the therapy in patients with coronary artery disease.
"The Kamakura Live Demonstration Course is an event to introduce to Japanese cardiologists new medical devices and practices intended to improve the treatment and the health of patients. Opsens' FFR products fit very well with this vision given the important benefits that they provide for efficiency and effectiveness in the treatment of coronary lesions. It was a great experience for me to demonstrate this new FFR system and I intend to continue using it", said Dr. Saito.
"Opsens' team is honoured to have their products used by Dr. Saito in the prestigious Kamakura Live Demonstration Course. The credibility of Dr. Saito and this event will be an asset to our marketing activities in Japan as well as around the world. Opsens is also pleased to announce that we have obtained a new regulatory approval in Japan for the latest generation of OptoWire. With this new generation FFR wire, we are now initiating our limited market launch with selected hospitals in Japan", said Louis Laflamme, President and CEO of Opsens.
Opsens aims at becoming a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire for FFR. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire delivering optimized performances to navigate coronary arteries and reach blockages with ease. Based on industry sources, the FFR market represented over US$250 million in sales in 2013 and is expected to reach US$1 billion in the medium-term. Opsens is confident that it is well positioned to capitalize on this significant growth opportunity.
The Company focuses mainly on two large and growing markets: the interventional cardiology and the oil and gas industry. In interventional cardiology, Opsens offers advanced optical based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Opsens also develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: OPSENS INC.
For further information:
Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996; Louis Laflamme, CPA, CA, Chief Executive Officer, 418.682.9996